SI
SI
discoversearch

 Biotech / Medical | Beat the Market Biotechs


Previous 10 | Next 10 
From: Western Rookie2/21/2012 2:27:11 PM
   of 72
 
Same team behind CFR is behind FLU... Watch for money to rollover into FLU after CFR run is done. ;)

FLU has a product that Cold Fx isn't going to be able to hold a candle to. You take aFASTFLU shot in a little bottle (5 hour energy size) sold for $3.99. It's Elderberry/ Saskatoon berry and the complete run down of the ColdFx ingredients plus other proprietary ingredients. Considering we served nearly 2,000 FASTFLU shots at the wellness show, it was very well received.

Should be licensed in June in time for next FLU season. Mike has already signed a couple of big seal oil/krill oil deals that is going to bring enough revenue to the company to qualify it for the venture. Add that the debenture that is in the works this company is set to rock and roll.

I think there might be news regarding a jv regarding krill oil jv as well.

Take a long hard look at it. I think it is well worth an $0.08 buy and hold in the TFSA/RRSP account.

Share Recommend | Keep | Reply | Mark as Last Read

From: Western Rookie2/21/2012 3:02:45 PM
   of 72
 

Abattis Biologix Corporation

CNSX : FLU




February 21, 2012 08:00 ET


Abattis Announces a Binding Letter of Agreement With Animo Wellness Corporation




VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 21, 2012) - Abattis Biologix Corporation (CNSX:FLU) (the "Company") is pleased to announce that it has entered into a binding letter of agreement (the "Letter of Agreement") with Animo Wellness Corporation ("Animo") for the Company's acquisition of 100% of the outstanding shares of Animo (the "Proposed Transaction"). Pursuant to the Letter of Agreement, the Company will acquire all of the issued and outstanding shares of Animo in consideration for which the Company (i) will issue to the shareholders of Animo an aggregate of 500,000 common shares of the Company (the "Payment Shares") at a deemed price of $0.075 per share; and (ii) will pay the shareholders of Animo an aggregate of $25,000.

The Letter of Agreement will be superseded by a definitive agreement to be negotiated by the parties. Completion of the Proposed Transaction is subject to certain conditions, including the receipt of any necessary regulatory approvals, the satisfactory completion of the Company's due diligence investigations, and such other closing conditions as are specified in the Letter of Agreement and as may be specified in the definitive agreement.

Animo Wellness Corp. is a privately held company that holds 75 Natural Health Product Licenses "NPNs" granted by Health Canada. These licenses range from "A" Acai to "V" Vitamin D. Mike Withrow, CEO of Abattis Biologix, states, "We are very pleased with this binding letter of agreement with Animo Wellness. This acquisition enables Abattis to legally produce and market a wide range of unique and mainstream natural health products. These will also enable Abattis to offer private label products to large customers."

About Abattis Biologix Corporation

Abattis Biologix Corporation is a growing and thriving specialty bio-technology life sciences company that has acquired intellectual property, and - on an ongoing basis - is conducting research, and working to develop proprietary health and wellness solutions that address chronic illnesses and disease in animals and humans through proprietary and patent pending formulations. The Company has identified targeted channels in which to market and license proprietary patent pending products throughout the world.

ON BEHALF OF THE COMPANY

Yazan Al Homsi, Director


Neither the CNSX nor its regulations services accepts responsibility for the adequacy or accuracy of this release.

Share Recommend | Keep | Reply | Mark as Last Read

From: Western Rookie2/22/2012 1:39:58 PM
   of 72
 
Scientists Fear Antibiotics are Perpetuating Diseases Impossible to Treat


Mike Barrett
NaturalSociety
February 21, 2012

Antibiotics, like many other drugs, are handed out by doctors as an end-all solution pill. Even for viral ailments doctors irresponsibly prescribe these pills as a solution. Unfortunately with all of the over-prescriptions and even necessary prescriptions, antibiotics have routinely been creating drug-resistant bacteria. Britain now seems to be facing their own massive increase in antibiotic-resistant blood poisoning caused by escherichia coli (E. coli).

Scientists Fear Antibiotics are Perpetuating Diseases Impossible to TreatBugs and bacteria rapidly adapt to survive, only taking months to for the genetic mutations to occur. Antibiotics, although successful in wiping out most of the bacterial invaders, don’t kill absolutely all of them. Over time the bacteria which survive the antibiotics become resistant, and continue to reproduce, only now with a quirk in their genetic structure allowing them to survive.



The slow but problematic growth of resistant organisms are resulting in antibiotics being nearly useless. The Independent reports:

Using standard antibiotic regimens, there is a one in 10 chance that treatment of an E.coli infection will fail because the bug is resistant. But, as numbers of resistant infections rise, there will be increasing pressure to use more powerful antibiotics, called carbapenems, which are the last line available. And resistance to those is already emerging…The warnings follow increasing reports from Europe of patients with infections that are almost impossible to treat.

But should this be a problem, as antibiotics, even if used in higher doses, are still killing off the invading bacteria? Sadly antibiotics do not discriminate against beneficial and bad bacteria. These medical giveaways are virtually depleting your body of all beneficial bacteria, leading to numerous health complications due to poor gut flora.

Antibiotics, linked to skyrocketing mental illness rates, are being identified as a player in the soaring obesity rates around the globe. In one study regarding the depletion of ‘good’ bacteria in the gut, researchers explained how antibiotics administered to mice ultimately resulted in altered behaviors far beyond diarrhea and pain.


With the combination of health complications and resistant superbugs, it is any wonder why antibiotics are still being used excessively. The drugs, making up what we at NaturalSociety like to call the disease machine, are perpetuating diseases that the medical establishment views as impossible to treat. All the while, their overuse is costing the National Health Service the equivalent of over $10.5 million per year.

naturalsociety.com

Share Recommend | Keep | Reply | Mark as Last Read


From: Western Rookie2/23/2012 5:22:05 AM
   of 72
 
Avivagen Announces U.S. Distribution Agreement
(via Thenewswire.ca)

OTTAWA, ONTARIO, February 16, 2012 - Teva Animal Health, Inc. (TAH) and Avivagen Animal Health, Inc. (AV), a Canadian Animal Health company, have entered into an exclusive U.S. veterinarian distribution agreement whereby TAH will become the exclusive distributor for Oximunol(TM) chewable tablets in the U.S. Oximunol(TM) Chewables are the first product developed by AV. TAH will participate in new product marketing efforts for Oximunol(TM) Chewables in the U.S. Terms of the agreement were not disclosed

About Avivagen

Avivagen, a Canadian company is the wholly-owned commercial subsidiary of Chemaphor, Inc. More information can be found at www.avivagen.com.

About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering products to animals and humans to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.chemaphor.com.

About Teva Animal Health

Teva Animal Health is an important provider of proprietary and generic products to the US animal health market, including products marketed under the DVM Pharmaceuticals brand. Teva is investing heavily in a comprehensive, phased renovation of its facilities bringing cGMP manufacturing capabilities that we believe are foremost in the animal health industry. This positions us well to move forward with an emphasis on branded products and value-added generics for the US animal health care market

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

David Hankinson Graham Burton, PhD

CEO, Chemaphor Inc. President and Co-Founder, Chemaphor Inc.

Phone: 902-825-9270 Phone: 613-990-0969

d.hankinson@chemaphor.com g.burton@chemaphor.com

Investor Relations: Media Group:

Advent Management Inc. McCormick Global Communications President & CEO Karen Sample

Sylvain Archambault 519-475-6378 1-877-906-2425 ksample@mccormickglobal.com s.archambault@go-advent.com www.mccormickglobal.com

Copyright (c) 2012 Thenewswire.ca - All rights reserved.

Share Recommend | Keep | Reply | Mark as Last Read

From: Western Rookie2/23/2012 5:23:18 AM
   of 72
 

biOasis Advances its Herceptin(R) BT2111 Program


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announced today that work is underway at Texas Tech University Health Sciences Center (TTUHSC) to perform a series of preclinical studies designed to evaluate the pharmacokinetics of BT2111 (a proprietary conjugate of p97 and Herceptin®) in animal models of breast cancer metastasis in the brain. The studies at TTUHSC will be conducted under the direction of Drs. Quentin Smith and Paul Lockman - both recognized experts in the blood-brain barrier and in evaluating drug delivery to the central nervous system for the treatment of brain tumors.

This program being conducted with TTUHSC follows on the results generated at the British Columbia Cancer Research Center showing that BT2111 had better in vitro cancer killing activity than Herceptin® alone and from animal studies conducted at the National Research Council (Ottawa) and the iCapture Centre (Vancouver), demonstrating a 10-fold increase in BT2111 transport into the brain compared with Herceptin® alone.

BT2111 is a conjugate between biOasis's Transcend brain delivery vector p97 and trastuzumab (trade name of Herceptin®), a humanized monoclonal antibody used clinically in the treatment of HER2+ breast cancer. It is reported that up to 30% of HER2+ breast cancer patients develop brain metastasis for which therapeutic options are limited. Because of its ability to cross the blood-brain barrier, biOasis is researching the potential of BT2111 for treatment of HER2+ metastatic breast cancer in the brain.

Herceptin® is a registered trademark of Genentech.

ABOUT BIOASIS

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the Company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more information about the Company please visit www.bioasis.ca.

Share Recommend | Keep | Reply | Mark as Last Read

From: Western Rookie2/23/2012 5:27:13 AM
   of 72
 
Stellar Biotechnologies Announces Significant Expansion of Keyhole Limpet Hatchery & Sera Production Capability

PORT HUENEME, CA--(Marketwire - December 06, 2011) - Stellar Biotechnologies, Inc. ("Stellar") (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) is pleased to announce the completion of a major expansion of its keyhole limpet (megathura crenulata) hatchery facility in Port Hueneme, CA in anticipation of increases in demand for its keyhole limpet hemocyanin (KLH) products. The hatchery expansion incorporates significant advances in aquaculture technology developed by the Company with support from the National Science Foundation (NSF), including methods for the control of the limpet reproductive cycle and systems for intensive propagation of the complex larval stages.

While estimates put the current total population of Megathura crenulata in the ocean available for commercial exploitation at less than 100,000 animals, this new facility has a spawning capacity of 2 million larvae and is designed to produce 50,000 juvenile limpets per year for Stellar.

This expansion will increase the Stellar's future KLH production capacity to in excess of 20,000 grams of KLH annually. Stellar estimates total current worldwide KLH usage at approximately 2,000 grams per year.

The Company's CEO, Frank Oakes, said, "This represents a major milestone in the Company's plan to provide a stable and scalable worldwide supply of KLH to support the commercialization of multiple KLH conjugate vaccines, as well as diagnostic and potential novel therapeutic products. While other KLH suppliers are planning for gram quantities of KLH to support preclinical research, and clinical vaccine development, Stellar is now capable of producing kilogram quantities of KLH to support all successful KLH platforms with GMP and non-GMP grade KLH as required by our customers."

Brandon Lincicum, Stellar's Aquaculture Manager, said, "It is very exciting to see the results of several years of intensive research supported by our NSF-SBIR grant translated into the world's first, fully-integrated keyhole limpet hatchery system with state-of-the-art technology and a dedicated team of well-trained, professional aquaculturists capable of supporting the large-scale commercial production that will be required by any vaccine developer that gets an approved product to the market."

Stellar Biotechnologies, Inc. (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) is the world leader in sustainable manufacturing of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.

Share Recommend | Keep | Reply | Mark as Last Read


From: Western Rookie2/23/2012 5:29:55 AM
   of 72
 
Neptune Premium Krill Oil, NKO(R) Enters the Mass Market With Jamieson Laboratories, the Largest Brand in Canada

LAVAL, Quebec, Feb. 15, 2012 (GLOBE NEWSWIRE) -- Neptune Technologies and Bioressources Inc. (Nasdaq:NEPT) (TSX-V:NTB) announces that Jamieson Laboratories (Jamieson) is initiating commercialisation of NKO® in the Canadian Food, Drug and Mass Market (FDM) retail channel coast to coast.

Jamieson, Canada's largest manufacturer and distributor of dietary supplements celebrates this year its 90th anniversary, confirming market leadership earned by consistently providing innovative products of the highest quality, purity and safety. Jamieson offers more than 250 different products in over 7,000 stores Nationwide.

'We are thrilled to introduce Jamieson Omega-3 Super Krill to the market. In accordance with the Jamieson brand, our Krill product contains 100% Neptune Krill Oil (NKO®), the only clinically proven krill oil with recognised Health Canada claims and specific health benefits. We are extremely confident that this new Jamieson product will benefit Canadian consumers who need to improve their cholesterol profile or alleviate a joint pain condition' stated Jillan Mariani, Director of Brand Marketing for Jamieson. "We have been watching krill as an ingredient for several years, and are bringing it to market at the right time and with the right partner" she added.

'This is a major achievement for Neptune; Jamieson is the number one distributor in Canada with an overwhelming presence in the Canadian mass-market. This new partnership represents a significant milestone in Neptune global growth strategy" said Michel Chartrand, Neptune's COO.

'After reviewing various options offered to us from competitive brands it was clear that Neptune Krill Oil was a superior product, surpassing others in all our judging criteria, making it easier to add NKO® to the Jamieson product portfolio' concluded Frank Lucchetta, Jamieson's Senior Vice-President.

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 30 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma (TSX-V:APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm Inc.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

Share Recommend | Keep | Reply | Mark as Last Read

From: Western Rookie2/23/2012 11:02:22 AM
   of 72
 
Avivagen Passes National Animal Supplement Council Certification Audit




from Thenewswire.ca - RSS (all) by news@thenewswire.ca (TheNewswire.ca)


OTTAWA, ONTARIO, February 23, 2012 - Avivagen Animal Health, a wholly-owned subsidiary of Chemaphor Inc. (the "Company"; TSX Venture Exchange: CFR), is pleased to announce that the National Animal Supplement Council (NASC) has awarded Avivagen Animal Health, Inc. (Avivagen) a compliance rating of "A" with a 2-year NASC Certification. As an NASC member, Avivagen Animal Health is now authorized to carry the NASC Quality Seal on Oximunol(TM) Chewables for dogs and on its other companion animal products currently in development, as well as to display the seal on its website. Avivagen's Oximunol(TM) Chewables are being sold in Canada and will be introduced to the US companion animal veterinary market later this year under the distribution agreement recently announced with Teva Animal Health, Inc.

"Receiving the NASC endorsement is a major company achievement for marketing our companion animal products in North America, and the US in particular," said David Hankinson, CEO of Chemaphor. "The audit was a rigorous and valuable process for Avivagen. Compliance with NASC's standards is all about providing a level of independent reassurance to customers that Avivagen manufactures its products to Good Manufacturing Practices standards and that it adheres to a complete set of written Standard Operating Procedures covering all aspects of the product, including manufacture, labeling, dissemination of product information in all forms, and the NASC Adverse Event Reporting System (NAERS). We are delighted with the excellent outcome of the evaluation of the processes we have in place to ensure production of the highest quality products."

About Avivagen

Avivagen Animal Health Inc., a wholly-owned subsidiary of Chemaphor, is a Canadian company dedicated to improving the quality of life of animals through science-based, natural health products proven in clinical trials. More information can be found at www.avivagen.com.

About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.chemaphor.com.

About NASC

The National Animal Supplement Council is a not-for-profit trade organization dedicated to protecting and enhancing the health of companion animals and horses throughout the United States through its ongoing effort to improve and standardize the animal health supplement industry. For more information please visit www.nasc.cc.

Forward Looking Statements This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

David Hankinson Graham Burton, PhD

CEO, Chemaphor Inc. President and Co-Founder, Chemaphor Inc.

Phone: 902-825-9270 Phone: 613-990-0969

d.hankinson@chemaphor.com g.burton@chemaphor.com

Investor Relations: Media Group:

Advent Management Inc. McCormick Global Communications President & CEO Karen Sample

Sylvain Archambault 519-475-6378 1-877-906-2425 ksample@mccormickglobal.com s.archambault@go-advent.com www.mccormickglobal.com

Share Recommend | Keep | Reply | Mark as Last Read

From: Western Rookie2/23/2012 11:50:51 PM
   of 72
 
Aker BioMarine posts 35% surge in sales of Superba krill oil in Q4, 2011


Aker BioMarine has posted a 35% surge in sales of Superba krill oil in the fourth quarter of 2011 – selling a record 70 metric tons compared with 52t in Q4, 2010.


nutraingredients-usa.com

Share Recommend | Keep | Reply | Mark as Last Read


From: Western Rookie2/27/2012 8:16:58 PM
   of 72
 

Bird flu cases more common than thought: study


AFP – Thu, Feb 23, 2012



Bird flu is believed to be a rare disease that kills more than half of the people it infects, but a US study out Thursday suggests it may be more common and less lethal than previously thought.

The research could help soothe concerns about the potential for a deadly pandemic that may kill many millions of people, sparked by the recent lab creation of a mutant bird flu that can pass between mammals.

Researchers at Mount Sinai School of Medicine in New York analyzed 20 previous international studies that tested the blood of nearly 13,000 participants worldwide, according to the study in the journal Science.

They found that between one and two percent of those tested showed evidence of a prior H5N1 avian flu infection, meaning millions of people may have been infected around the globe.

The World Health Organization's figures currently show just 573 cases in 15 countries since 2003, with 58.6 percent of those resulting in death.

The researchers said the WHO may be overlooking cases by focusing only on hospitalizations and severe illnesses, and recommended a new approach to calculating the true number of bird flu cases.

The findings could also mean that the death rate from bird flu is underestimated, largely because many of the people who get sick from it live in rural farming areas where medical care may be difficult to come by.

"We suggest that further investigation, on a large scale and by a standardized approach, is warranted to better estimate the total number of H5N1 infections that have occurred in humans," the authors wrote.

Researchers in the Netherlands and the United States have sparked international alarm with lab research that was successful in creating a mutant form of bird flu that was found to be transmissible among ferrets.

US health authorities have urged major science journals to publish only heavily edited forms of the studies in order to prevent the data from falling into terrorists' hands.

However, an international group of experts meeting at WHO headquarters in Geneva last week decided that the studies should eventually be published in full, but that a further risk assessment is needed before that can happen.

Share Recommend | Keep | Reply | Mark as Last Read
Previous 10 | Next 10 

Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.